Bihua Chen - 22 Jun 2022 Form 4 Insider Report for Erasca, Inc. (ERAS)

Role
Director
Signature
/s/ Bihua Chen
Issuer symbol
ERAS
Transactions as of
22 Jun 2022
Net transactions value
$0
Form type
4
Filing time
24 Jun 2022, 16:04:05 UTC
Previous filing
07 Apr 2022
Next filing
21 Dec 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding ERAS Common Stock 10,505,554 22 Jun 2022 See Footnotes F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ERAS Stock Option (right to buy) Award $0 +40,000 $0.000000 40,000 22 Jun 2022 Common Stock 40,000 $5.35 Direct F4
holding ERAS Stock Option (right to buy) 166,666 22 Jun 2022 Common Stock 166,666 $5.81 Direct F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Shares reported herein are held by Cormorant Global Healthcare Master Fund, LP (the "Master Fund"), Cormorant Private Healthcare Fund II, LP ("Fund II"), and a managed account (the "Account"). Cormorant Asset Management, LP ("Cormorant") serves as the investment manager of the Master Fund, Fund II, and the Account. Bihua Chen serves as manager of the general partner of Cormorant. Ms. Chen disclaims beneficial ownership of the shares reported herein except to the extent of her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that Ms. Chen is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose.
F2 Represents (i) 2,678,710 shares of Common Stock held by the Master Fund, (ii) 7,716,444 shares of Common Stock held by Fund II, and (iii) 110,400 shares of Common Stock held by the Account.
F3 Stock option grant for 166,666 shares, 41,667 shares of which became exercisable on 3/16/2022 and 124,999 shares of which are exercisable thereafter in equal monthly installments through 3/16/2025.
F4 Stock options granted to Ms. Chen, in her capacity as a director of the Issuer.